The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: A case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies

British Journal of Dermatology

Volumn 167, Issue 3, 2012, Pages 555-562

  Lee, H Y ^a   Dunant, A ^b,c   Sekula, P ^d   Mockenhaupt, M ^d   Wolkenstein, P ^b   Valeyrie Allanore, L ^b   Naldi, L ^e   Halevy, S ^f   Roujeau, J C ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

^e OSPEDALI RIUNITI   (Italy)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; LAMOTRIGINE; NEVIRAPINE; OXICAM DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; SULFONAMIDE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; ONSET AGE; PATIENT SELECTION; PRIORITY JOURNAL; SECONDARY ANALYSIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADRENAL CORTEX HORMONES; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 84865577289     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11074.x     Document Type: Article

References (25)

1. Roujeau JC, Stern RS,. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85. (Pubitemid 24333193)
2. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-6. (Pubitemid 23029676)
3. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37-42.
4. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-73. (Pubitemid 26280728)
5. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5. (Pubitemid 17119309)
6. Schoepf E, Stuehmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42.
7. Mockenhaupt M, Norgauer J,. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002; 14: 143-50. (Pubitemid 34753025)
8. Mockenhaupt M,. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7: 803-13.
9. Kardaun SH, Jonkman MF,. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87: 144-8. (Pubitemid 46513200)
10. Van der Meer JB, Schuttelaar ML, Toth GG, et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 2001; 26: 654-6. (Pubitemid 33070419)
11. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3. (Pubitemid 28483679)
12. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM,. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121: 1548-9. (Pubitemid 16202174)
13. Arevalo JM, Jorente JA, Gonzalez-Herrada C, Jimenez-Reyes J,. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-8. (Pubitemid 30183110)
14. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163: 847-53.
15. Heng MCY, Allen SG,. Efficacy of cyclophosphamide in toxic epidermal necrolysis, clinical and pathophysiologic aspects. J Am Acad Dermatol 1991; 25: 778-86.
16. Wolff K, Tappeiner G,. Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing. Arch Dermatol 2003; 139: 85-6. (Pubitemid 36091582)
17. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995; 131: 669-72.
18. Rzany B, Schmitt H, Schoepf E,. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71: 171-2.
19. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 2008; 128: 35-44. (Pubitemid 350249390)
20. Halebian PH, Corder VJ, Madded MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12. (Pubitemid 17176768)
21. Kelemen JJ, Cioffi WG, McManus MR, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273-8.
22. Herndon DN,. Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995; 180: 340-2.
23. Schneck J, Fagot JP, Sekula P, et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40. (Pubitemid 350298143)
24. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-50.
25. Xu L, Xu Z, Xu M,. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis. Clin Exp Immunol 2009; 158: 26-30.